Genetic risk prediction for hereditary ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to establish a multicenter cohort of hereditary ovarian cancer patients in China to analyze their clinicopathologic features and develop a risk prediction model. By following up on clinical and pathological data, genetic test results, and family histories, the study seeks to quantify cancer risk in first-degree relatives of mutation carriers. Additionally, it aims to identify novel tumor-causing mutations and predisposing genes through gene sequencing in families with hereditary tumors. The ultimate goal is to guide preventive interventions for high-risk populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Epithelial ovarian cancer
* ≥18 years
* The pathological diagnosis was clear
* The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation)

Exclusion Criteria:

* Non-epithelial ovarian cancer was confirmed by pathology
* No genetic test has been performed

Where it's running

• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Hongyan Guo, Doctor — Peking University Third Hospital
• Study coordinator: Yuan Li, Doctor
• Email: yuanli@bimu.edu.cn
• Phone: 18610689868

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Mocertatug Rezetecan with Bevacizumab vs Platinum Doublet with Bevacizumab in Platinum-Sensitive Ovarian Cancer

  This trial tests whether mocertatug rezetecan plus bevacizumab helps people with platinum-sensitive ovarian cancer respond better than standard platinum-based therapy plus bevacizumab.

  Recruiting at 9 sites Phase 3 GlaxoSmithKline · Newcastle, New South Wales and 8 other locations · NCT07684612

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Mocertatug Rezetecan vs Standard Care for Platinum-Resistant Ovarian Cancer

  This study tests mocertatug rezetecan (Mo-Rez) against standard treatments to see if it helps people with platinum-resistant ovarian cancer behave better and handle side effects.

  Recruiting at 22 sites Phase 3 GlaxoSmithKline · Randwick, New South Wales and 21 other locations · NCT07286266

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.